NCT05607095View on ClinicalTrials.gov

A Study of LN-144 or LN-145 in People With Advanced Uveal Melanoma, Undifferentiated Pleomorphic Sarcoma, or Dedifferentiated Liposarcoma

PHASE1RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

November 1, 2022

Primary Completion Date

May 1, 2026

Study Completion Date

May 1, 2026

Conditions
Uveal MelanomaMelanomaMetastatic Uveal MelanomaMetastatic Melanoma
Interventions
BIOLOGICAL

Lifileucel (LN-144/LN-145)

Lifileucel (LN-144/LN-145) is an autologous Tumor Infiltrating Lymphocytes (TIL) cell therapy that utilizes a 22-day centralized GMP process. Lifileucel is infused as part of a treatment regimen that includes preparative NMA-LD, followed by one-time autologous TIL infusion, and a short course of high-dose IL-2.

Trial Locations (2)

10065

RECRUITING

Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York

10604

RECRUITING

Memorial Sloan Kettering Westchester, Harrison

Sponsors
All Listed Sponsors
collaborator

Iovance Biotherapeutics, Inc.

INDUSTRY

lead

Memorial Sloan Kettering Cancer Center

OTHER

NCT05607095 - A Study of LN-144 or LN-145 in People With Advanced Uveal Melanoma, Undifferentiated Pleomorphic Sarcoma, or Dedifferentiated Liposarcoma | Biotech Hunter | Biotech Hunter